Course Description
Join us for an hour of learning on July 15, 2026 at 11 AM Central
(12 PM Eastern/10 AM Mountain/9 AM Pacific)
Clozapine remains the most effective treatment for treatment-resistant schizophrenia. Despite well-recognized variability in clozapine metabolism and the strongest recommendation to use TDM, it still remains inconsistently incorporated into routine clinical practice. Pharmacists have long led therapeutic drug monitoring initiatives in areas such as antimicrobial stewardship, transplant medicine, and oncology, translating pharmacokinetic principles into safer, more effective patient care. With rapid clozapine testing now available, pharmacists are uniquely positioned to bring the same evidence-based approach to personalized clozapine management. The question is no longer whether clozapine levels are useful, it is how pharmacists can lead their integration into routine care.
Attendees will hear from Jordan Reese, PharmD, BCPP, who successfully led the implementation of a real-time clozapine titration and monitoring program at Colorado Mental Health Hospital in Pueblo, sharing practical lessons on overcoming barriers, building multidisciplinary support, and integrating TDM into clinical workflows.
Megan Ehret, PharmD, MS, BCPP, FAAPP, and Jordan Reese, PharmD, BCPP, will review how rapid TDM can support clinical decision-making throughout the patient journey, including dose optimization, assessment of non-response, evaluation of adherence, management of toxicity, interpretation of drug interactions, smoking-related metabolic changes, and re-titration following treatment interruption.
Participants will leave with practical tools to implement and interpret clozapine TDM programs and a deeper understanding of how pharmacists can lead practice change and advance personalized clozapine therapy.
Learning Objectives
- Describe the clinical rationale for incorporating TDM into clozapine management and identify situations where rapid TDM can improve patient care.
- Understand key steps in designing and implementing a pharmacist-led real-time clozapine TDM workflow.
- Learn how to apply clozapine concentration data to support individualized dosing decisions across a variety of clinical scenarios.
- Identify strategies pharmacists can use to overcome implementation barriers and lead practice change.
Target Audience
If you are a pharmacist, nurse practitioner, or other health care professional involved in the comprehensive medication management of individuals living with mental health and/or substance use disorders, we invite you to participate in this online course.
Faculty
View biographical information
Jordan Reese, PharmD, BCPP
Clinical Pharmacy Specialist at Colorado Mental Health Hospital in Pueblo (CMHHIP)
Megan Ehret, PharmD, MS, BCPP, FAAPP
Professor, Co-Director of the Mental Health Program, Vice-Chair of Academic Affairs, University of Maryland, School of Pharmacy
Continuing Education Credit and Disclosures
View AAPP's Disclaimer and Disclosure Declarations
AAPP Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Unlabeled Use Disclosure: Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. The faculty, planners, and American Association of Psychiatric Pharmacists do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
View AAPP's Copyright Statement, Terms of Use, and Policies
AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.
View AAPP's Privacy Policy. AAPP's Terms of Use and other policies on education programs, resources, toolkits, and other web based content/offerings are available here.
View AAPP's Fair Balance and Integrity Statement
It is the policy of AAPP to ensure independence, balance, objectivity, scientific rigor, and integrity in continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer’s package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.
Fair balance is achieved through ongoing and thorough review of all materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by AAPP for any product or manufacturer identified.
This industry virtual showcase is supported by
